$0.17
0.12% today
Nasdaq, Apr 03, 06:37 pm CET
ISIN
US09057N2018
Symbol
BPTH
Sector
Industry

Bio-Path Holdings, Inc. Stock price

$0.17
-0.01 4.38% 1M
-0.71 80.71% 6M
-0.99 85.33% YTD
-4.06 95.98% 1Y
-79.83 99.79% 3Y
-93.63 99.82% 5Y
-7,079.83 100.00% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.01 3.15%
ISIN
US09057N2018
Symbol
BPTH
Sector
Industry

Key metrics

Market capitalization $1.37m
Enterprise Value $280.00k
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 6.18
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-11.99m
Free Cash Flow (TTM) Free Cash Flow $-10.58m
Cash position $1.17m
EPS (TTM) EPS $-7.22
Short interest 1.38%
Show more

Is Bio-Path Holdings, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Bio-Path Holdings, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Bio-Path Holdings, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Bio-Path Holdings, Inc.:

Buy
100%

Financial data from Bio-Path Holdings, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.16 0.16
11% 11%
-
-0.16 -0.16
11% 11%
-
- Selling and Administrative Expenses 4.38 4.38
13% 13%
-
- Research and Development Expense 7.30 7.30
37% 37%
-
-12 -12
25% 25%
-
- Depreciation and Amortization 0.16 0.16
11% 11%
-
EBIT (Operating Income) EBIT -12 -12
24% 24%
-
Net Profit -9.89 -9.89
38% 38%
-

In millions USD.

Don't miss a Thing! We will send you all news about Bio-Path Holdings, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bio-Path Holdings, Inc. Stock News

Neutral
GlobeNewsWire
6 days ago
HOUSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced its financial results for the year ended December 31, 2024 and provided an update on recent corporate developments. “We are...
Neutral
GlobeNewsWire
16 days ago
Recent Pre-Clinical Studies Showed BP1001-A Attenuated Fatty Acid-Induced Insulin Resistance and Restored Insulin Sensitivity in Muscle Progenitor and Skeletal Muscle Fiber Cell Models Recent Pre-Clinical Studies Showed BP1001-A Attenuated Fatty Acid-Induced Insulin Resistance and Restored Insulin Sensitivity in Muscle Progenitor and Skeletal Muscle Fiber Cell Models
Neutral
GlobeNewsWire
about 2 months ago
First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable Disease
More Bio-Path Holdings, Inc. News

Company Profile

Bio-Path Holdings, Inc. is a biotechnology company, which engages in the develpment of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline include Prexigebersen, BP1002, and BP1003. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.

Head office United States
CEO Peter Nielsen
Employees 10
Founded 2007
Website www.biopathholdings.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today